文献速递湿疹皮炎与荨麻疹

慢性荨麻疹对患者与社会的全球负担

The global burden of chronic urticaria for the patient and society.
PubMed 文献 · Br J Dermatol · 2020-11-02

慢性荨麻疹影响全球约1%人口,多为中青年女性,病程常持续数年且管理延迟。超过25%病例对高剂量H1抗组胺药抵抗,奥马珠单抗和环孢素仅控制三分之二抵抗患者。该病显著损害健康相关生活质量,合并焦虑抑郁超30%,并带来高额直接与间接经济负担。

要点

  • 慢性荨麻疹常持续数年,25-75%患者病程超过1年,且有效管理常延迟。
  • 超过25%病例对高剂量H1抗组胺药抵抗,三/四线治疗仅控制三分之二。
  • 30%患者皮肤病生活质量指数>10,焦虑抑郁合并率超30%。

核心结论

  • 慢性荨麻疹对患者健康相关生活质量有显著影响,并造成高额社会经济负担。

研究设计与样本

  • 本文为综述,总结慢性荨麻疹对患者生活质量及社会负担的影响。

主要发现

  • 慢性荨麻疹影响全球约1%人口,多为中青年女性,25-75%患者病程超过1年。
  • 超过25%病例对高剂量H1抗组胺药抵抗,三/四线治疗仅控制三分之二抵抗患者。
  • 30%患者皮肤病生活质量指数>10,焦虑抑郁合并率超30%,并导致睡眠障碍、性功能障碍及工作学习受损(缺勤6%,出勤主义25%)。

临床怎么用

  • 临床应关注慢性荨麻疹对生活质量的广泛影响,包括睡眠、性功能、工作及心理合并症。
  • 对高剂量H1抗组胺药抵抗患者,需考虑奥马珠单抗或环孢素等三/四线治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society. CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment. Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism). Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2020. PMID: 32956489. doi:10.1111/bjd.19561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。